FDA approves Moderna’s mRNA RSV vaccine for older adults
May 31, 2024 · CNN — The US Food and Drug Administration has approved another vaccine to help protect older people from respiratory syncytial virus, known as RSV. The shot, made by Moderna and sold under the...
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
May 31, 2024 · mRESVIA (Respiratory Syncytial Virus Vaccine) is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older.
Moderna says its RSV shot is 50% effective across a second season
Jun 26, 2024 · Moderna Inc respiratory syncytial virus (RSV) shot mRESVIA showed 50% efficacy in preventing RSV after 18 months, the drugmaker said on Wednesday.
FDA Approves Moderna RSV Vaccine, an mRNA Alternative to ... - MedCity News
May 31, 2024 · Moderna’s mResvia is now the third FDA-approved RSV vaccine and the first one based on mRNA technology. It will compete for market share against RSV shots from GSK and Pfizer that won...
MRESVIA | FDA - U.S. Food and Drug Administration
Oct 4, 2024 · MRESVIATM is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age...
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
May 31, 2024 · CAMBRIDGE, MA / ACCESSWIRE / May 31, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory...
Moderna Receives European Commission Approval for RSV Vaccine mRESVIA…
Aug 23, 2024 · In May 2024, the U.S. Food and Drug Administration (FDA) approved mRESVIA (mRNA-1345) to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marked Moderna's second approved mRNA product.
News Details
6 days ago · mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA following approvals in the U.S., Europe, and Qatar CAMBRIDGE, MA / ACCESSWIRE / November 8, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced Health Canada has approved mRESVIA™ (Respiratory ...
FDA approves Moderna’s RSV vaccine, its second licensed product …
May 31, 2024 · The Moderna RSV vaccine, which will be marketed under the name mResvia, was approved for adults 60 and older. It is made using the same messenger RNA platform as Moderna’s other licensed product...
FDA Approves mRNA-Based RSV Vaccine mResvia - Infectious …
Jun 3, 2024 · The Food and Drug Administration (FDA) has approved mResvia (respiratory syncytial virus vaccine) for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus …